418 related articles for article (PubMed ID: 12954121)
1. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors.
Sharifi J; Khawli LA; Hu P; King S; Epstein AL
Hybrid Hybridomics; 2001; 20(5-6):305-12. PubMed ID: 11839248
[TBL] [Abstract][Full Text] [Related]
3. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors.
Hornick JL; Sharifi J; Khawli LA; Hu P; Biela BH; Mizokami MM; Yun A; Taylor CR; Epstein AL
Cancer Biother Radiopharm; 1998 Aug; 13(4):255-68. PubMed ID: 10850361
[TBL] [Abstract][Full Text] [Related]
4. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
[TBL] [Abstract][Full Text] [Related]
5. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.
Hornick JL; Khawli LA; Hu P; Sharifi J; Khanna C; Epstein AL
Clin Cancer Res; 1999 Jan; 5(1):51-60. PubMed ID: 9918202
[TBL] [Abstract][Full Text] [Related]
7. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors.
Khawli LA; Biela B; Hu P; Epstein AL
Hybrid Hybridomics; 2003 Feb; 22(1):1-9. PubMed ID: 12713684
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E
Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin.
Khawli LA; Mizokami MM; Sharifi J; Hu P; Epstein AL
Cancer Biother Radiopharm; 2002 Aug; 17(4):359-70. PubMed ID: 12396700
[TBL] [Abstract][Full Text] [Related]
10. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
11. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
[TBL] [Abstract][Full Text] [Related]
12. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
13. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells.
Khawli LA; Biela BH; Hu P; Epstein AL
Hybrid Hybridomics; 2002 Feb; 21(1):11-8. PubMed ID: 11991812
[TBL] [Abstract][Full Text] [Related]
14. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins.
Sharifi J; Khawli LA; Hu P; Li J; Epstein AL
Hybrid Hybridomics; 2002 Dec; 21(6):421-32. PubMed ID: 12573106
[TBL] [Abstract][Full Text] [Related]
15. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
de Graaf M; Boven E; Oosterhoff D; van der Meulen-Muileman IH; Huls GA; Gerritsen WR; Haisma HJ; Pinedo HM
Br J Cancer; 2002 Mar; 86(5):811-8. PubMed ID: 11875747
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
17. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
18. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
20. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
